CORONA Remedies (CORONA) investor relations material

Executive summary

• Achieved 21.9% year-over-year revenue growth in Q1 FY 2027, with revenue of INR 422.43 crore and PAT of INR 60.11 crore, marking the fourth consecutive quarter of robust growth.

• Fastest growing among top 30 pharma companies in IPM, improving rank to 26th in MAT June-26.

• Chronic and semi-chronic therapies contributed 73.4% of Q1 FY27 revenue, with leadership in women's healthcare, pain management, urology, and cardiometabolic segments.

• Growth was broad-based, driven by volume, price, and new product introductions, with strong brand building and market execution.

• Successfully commercialized India's most advanced EU-GMP-approved women's hormone manufacturing facility and renewed EU-GMP certification for oral solid dosage plant.

Financial highlights

• Q1 FY 2027 revenue: INR 422.43 crore, up from INR 346.54 crore in Q1 FY 2026 (21.9% growth).

• EBITDA: INR 93.1 crore, up 33.5% year-over-year; EBITDA margin improved by 190 bps to 22%.

• Profit after tax: INR 60.11 crore, up 30.1% year-over-year; PAT margin increased by 90 bps to 14.2%.

• EPS for Q1FY27 at 9.8 (not annualized); consolidated, basic and diluted EPS at ₹9.83.

• ROCE (annualized) at 50.2% and ROE at 34.0%.

Outlook and guidance

• Targeting 15% organic revenue growth and 20% PAT growth for FY 2027, with an additional 1.5%-2% inorganic revenue growth expected.

• Plans to increase market share in domestic IPM, expand into new therapeutic areas, and grow women's health and overseas markets leveraging hormone product portfolio.

• Hormone facility expected to drive both domestic and, from FY 2029, international growth.

• Company continues to monitor regulatory developments regarding new Labour Codes and will adjust accounting as needed.